Zogenix, Inc. Logo

Zogenix, Inc.

0M3O.L

(0.0)
Stock Price

40,75 USD

0% ROA

10.55% ROE

0x PER

Market Cap.

0,00 USD

0% DER

0% Yield

4.99% NPM

Zogenix, Inc. Stock Analysis

Zogenix, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Zogenix, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Zogenix, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Zogenix, Inc. Technical Stock Analysis
# Analysis Recommendation

Zogenix, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Zogenix, Inc. Revenue
Year Revenue Growth
2012 7.183.200.000
2013 7.436.600.000 3.41%
2014 8.305.100.000 10.46%
2015 8.023.200.000 -3.51%
2016 9.071.000.000 11.55%
2017 9.799.000.000 7.43%
2018 10.530.000.000 6.94%
2019 10.168.000.000 -3.56%
2020 10.165.000.000 -0.03%
2021 14.838.000.000 31.49%
2022 15.801.000.000 6.09%
2023 14.488.000.000 -9.06%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Zogenix, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 309.300.000
2013 350.400.000 11.73%
2014 392.800.000 10.79%
2015 386.200.000 -1.71%
2016 417.800.000 7.56%
2017 473.000.000 11.67%
2018 512.000.000 7.62%
2019 498.000.000 -2.81%
2020 533.000.000 6.57%
2021 930.000.000 42.69%
2022 968.000.000 3.93%
2023 860.000.000 -12.56%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Zogenix, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Zogenix, Inc. EBITDA
Year EBITDA Growth
2012 1.125.900.000
2013 1.224.100.000 8.02%
2014 1.398.300.000 12.46%
2015 1.362.300.000 -2.64%
2016 1.511.200.000 9.85%
2017 1.630.000.000 7.29%
2018 1.729.000.000 5.73%
2019 1.642.000.000 -5.3%
2020 1.509.000.000 -8.81%
2021 2.224.000.000 32.15%
2022 2.242.000.000 0.8%
2023 1.520.000.000 -47.5%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Zogenix, Inc. Gross Profit
Year Gross Profit Growth
2012 1.466.900.000
2013 1.557.500.000 5.82%
2014 1.756.400.000 11.32%
2015 1.703.100.000 -3.13%
2016 1.928.700.000 11.7%
2017 2.115.000.000 8.81%
2018 2.230.000.000 5.16%
2019 2.101.000.000 -6.14%
2020 1.910.000.000 -10%
2021 2.855.000.000 33.1%
2022 3.101.000.000 7.93%
2023 2.608.000.000 -18.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Zogenix, Inc. Net Profit
Year Net Profit Growth
2012 500.900.000
2013 624.300.000 19.77%
2014 655.800.000 4.8%
2015 609.700.000 -7.56%
2016 595.000.000 -2.47%
2017 440.000.000 -35.23%
2018 931.000.000 52.74%
2019 746.000.000 -24.8%
2020 500.000.000 -49.2%
2021 537.000.000 6.89%
2022 944.000.000 43.11%
2023 348.000.000 -171.26%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Zogenix, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 2
2013 3 0%
2014 3 0%
2015 3 0%
2016 3 0%
2017 2 0%
2018 4 50%
2019 4 -33.33%
2020 2 -50%
2021 2 0%
2022 4 33.33%
2023 1 -200%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Zogenix, Inc. Free Cashflow
Year Free Cashflow Growth
2012 471.300.000
2013 301.000.000 -56.58%
2014 238.800.000 -26.05%
2015 290.600.000 17.83%
2016 535.100.000 45.69%
2017 620.000.000 13.69%
2018 580.000.000 -6.9%
2019 527.000.000 -10.06%
2020 723.000.000 27.11%
2021 638.000.000 -13.32%
2022 846.000.000 24.59%
2023 72.000.000 -1075%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Zogenix, Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 878.700.000
2013 718.800.000 -22.25%
2014 801.800.000 10.35%
2015 867.900.000 7.62%
2016 1.035.700.000 16.2%
2017 1.180.000.000 12.23%
2018 1.126.000.000 -4.8%
2019 1.008.000.000 -11.71%
2020 1.184.000.000 14.86%
2021 1.306.000.000 9.34%
2022 1.569.000.000 16.76%
2023 176.000.000 -791.48%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Zogenix, Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 407.400.000
2013 417.800.000 2.49%
2014 563.000.000 25.79%
2015 577.300.000 2.48%
2016 500.600.000 -15.32%
2017 560.000.000 10.61%
2018 546.000.000 -2.56%
2019 481.000.000 -13.51%
2020 461.000.000 -4.34%
2021 668.000.000 30.99%
2022 723.000.000 7.61%
2023 104.000.000 -595.19%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Zogenix, Inc. Equity
Year Equity Growth
2012 3.146.100.000
2013 3.632.400.000 13.39%
2014 3.690.900.000 1.58%
2015 3.631.500.000 -1.64%
2016 3.301.900.000 -9.98%
2017 3.825.900.000 13.7%
2018 4.345.000.000 11.95%
2019 4.844.000.000 10.3%
2020 6.724.000.000 27.96%
2021 7.262.000.000 7.41%
2022 7.508.000.000 3.28%
2023 6.007.000.000 -24.99%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Zogenix, Inc. Assets
Year Assets Growth
2012 6.400.800.000
2013 6.917.000.000 7.46%
2014 7.228.000.000 4.3%
2015 8.825.700.000 18.1%
2016 8.834.700.000 0.1%
2017 9.787.600.000 9.74%
2018 10.095.000.000 3.05%
2019 9.702.000.000 -4.05%
2020 16.029.000.000 39.47%
2021 16.575.000.000 3.29%
2022 16.994.000.000 2.47%
2023 14.104.000.000 -20.49%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Zogenix, Inc. Liabilities
Year Liabilities Growth
2012 3.254.700.000
2013 3.284.600.000 0.91%
2014 3.537.100.000 7.14%
2015 5.194.200.000 31.9%
2016 5.532.800.000 6.12%
2017 5.961.700.000 7.19%
2018 5.750.000.000 -3.68%
2019 4.858.000.000 -18.36%
2020 9.305.000.000 47.79%
2021 9.313.000.000 0.09%
2022 9.486.000.000 1.82%
2023 8.097.000.000 -17.15%

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Zogenix, Inc. Dividends
Year Dividends Growth
2022 0

Zogenix, Inc. Profile

About Zogenix, Inc.

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

CEO
Dr. Stephen Farr
Employee
218
Address
5959 Horton St Ste 500
Emeryville, 94608

Zogenix, Inc. Executives & BODs

Zogenix, Inc. Executives & BODs
# Name Age

Zogenix, Inc. Competitors